

Neal D Shore, Facs

List of Publications by Citations

Source: <https://exaly.com/author-pdf/367078/neal-d-shore-facs-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

130
papers

14,634
citations

38
h-index

120
g-index

137
ext. papers

18,171
ext. citations

7.9
avg, IF

6.12
L-index

#	Paper	IF	Citations
130	Sipuleucel-T immunotherapy for castration-resistant prostate cancer. <i>New England Journal of Medicine</i> , 2010 , 363, 411-22	59.2	3838
129	Increased survival with enzalutamide in prostate cancer after chemotherapy. <i>New England Journal of Medicine</i> , 2012 , 367, 1187-97	59.2	3075
128	Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. <i>Lancet, The</i> , 2011 , 377, 813-22	40	1443
127	Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. <i>Lancet Oncology, The</i> , 2015 , 16, 152-60	21.7	856
126	Olaparib for Metastatic Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , 2020 , 382, 2091-2102	59.2	550
125	Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , 2018 , 378, 2465-2474	59.2	525
124	Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , 2019 , 380, 1235-1246	59.2	380
123	Management of Patients with Advanced Prostate Cancer: The Report of the Advanced Prostate Cancer Consensus Conference APCCC 2017. <i>European Urology</i> , 2018 , 73, 178-211	10.2	313
122	ARCHES: A Randomized, Phase III Study of Androgen Deprivation Therapy With Enzalutamide or Placebo in Men With Metastatic Hormone-Sensitive Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2019 , 37, 2974-2986	2.2	285
121	Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). <i>European Urology</i> , 2014 , 66, 815-25	10.2	186
120	Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study. <i>Lancet Oncology, The</i> , 2016 , 17, 153-163	21.7	164
119	Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. <i>European Urology</i> , 2020 , 77, 508-547	10.2	155
118	Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3800-6	2.2	145
117	Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , 2020 , 383, 2345-2357	59.2	143
116	The prostatic urethral lift for the treatment of lower urinary tract symptoms associated with prostate enlargement due to benign prostatic hyperplasia: the L.I.F.T. Study. <i>Journal of Urology</i> , 2013 , 190, 2161-7	2.5	125
115	Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. <i>Lancet Oncology, The</i> , 2013 , 14, 1193-9	21.7	123
114	Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , 2020 , 382, 2197-2206	59.2	114

113	Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer. <i>New England Journal of Medicine</i> , 2020 , 382, 2187-2196	59.2	109
112	Minimally Invasive Prostate Convective Water Vapor Energy Ablation: A Multicenter, Randomized, Controlled Study for the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. <i>Journal of Urology</i> , 2016 , 195, 1529-1538	2.5	107
111	Role of Genetic Testing for Inherited Prostate Cancer Risk: Philadelphia Prostate Cancer Consensus Conference 2017. <i>Journal of Clinical Oncology</i> , 2018 , 36, 414-424	2.2	107
110	Five year results of the prospective randomized controlled prostatic urethral L.I.F.T. study. <i>Canadian Journal of Urology</i> , 2017 , 24, 8802-8813	0.8	101
109	Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide. <i>New England Journal of Medicine</i> , 2020 , 383, 1040-1049	59.2	96
108	Intravesical rAd-IFN γ /Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3410-3416	2.2	86
107	Hypocalcaemia in patients with metastatic bone disease treated with denosumab. <i>European Journal of Cancer</i> , 2015 , 51, 1812-21	7.5	84
106	Managing Nonmetastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2019 , 75, 285-293	10.2	83
105	Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort. <i>European Urology</i> , 2016 , 70, 963-970	10.2	78
104	Challenges and recommendations for early identification of metastatic disease in prostate cancer. <i>Urology</i> , 2014 , 83, 664-9	1.6	70
103	A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2015 , 21, 3862-9	12.9	62
102	Radium-223 Safety, Efficacy, and Concurrent Use with Abiraterone or Enzalutamide: First U.S. Experience from an Expanded Access Program. <i>Oncologist</i> , 2018 , 23, 193-202	5.7	51
101	Absorbable Hydrogel Spacer Use in Prostate Radiotherapy: A Comprehensive Review of Phase 3 Clinical Trial Published Data. <i>Urology</i> , 2018 , 115, 39-44	1.6	51
100	Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men with Hormone-Sensitive Biochemically Recurrent Prostate Cancer: A Phase II Randomized Trial. <i>Clinical Cancer Research</i> , 2017 , 23, 2451-2459	12.9	48
99	Survival of African-American and Caucasian men after sipuleucel-T immunotherapy: outcomes from the PROCEED registry. <i>Prostate Cancer and Prostatic Diseases</i> , 2020 , 23, 517-526	6.2	48
98	Impact of the Cell Cycle Progression Test on Physician and Patient Treatment Selection for Localized Prostate Cancer. <i>Journal of Urology</i> , 2016 , 195, 612-8	2.5	45
97	Subsequent Chemotherapy and Treatment Patterns After Abiraterone Acetate in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. <i>European Urology</i> , 2017 , 71, 656-664	10.2	44
96	Impact of Centralizing Care for Genitourinary Malignancies to High-volume Providers: A Systematic Review. <i>European Urology Oncology</i> , 2019 , 2, 265-273	6.7	44

95	Long-term tolerability and efficacy of degarelix: 5-year results from a phase III extension trial with a 1-arm crossover from leuprolide to degarelix. <i>Urology</i> , 2014 , 83, 1122-8	1.6	41
94	Impact of bone-targeted therapies in chemotherapy-naïve metastatic castration-resistant prostate cancer patients treated with abiraterone acetate: post hoc analysis of study COU-AA-302. <i>European Urology</i> , 2015 , 68, 570-7	10.2	41
93	Darolutamide (ODM-201) for the treatment of prostate cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2017 , 18, 945-952	4	40
92	A Clinician@ Guide to Next Generation Imaging in Patients With Advanced Prostate Cancer (RADAR III). <i>Journal of Urology</i> , 2019 , 201, 682-692	2.5	38
91	The IMAAGEN Study: Effect of Abiraterone Acetate and Prednisone on Prostate Specific Antigen and Radiographic Disease Progression in Patients with Nonmetastatic Castration Resistant Prostate Cancer. <i>Journal of Urology</i> , 2018 , 200, 344-352	2.5	37
90	Radium-223 dichloride for metastatic castration-resistant prostate cancer: the urologist@ perspective. <i>Urology</i> , 2015 , 85, 717-24	1.6	37
89	Evaluation of Clinically Relevant Drug-Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial. <i>Targeted Oncology</i> , 2019 , 14, 527-539	5	35
88	Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer. <i>Cancer</i> , 2019 , 125, 4172-4180	6.4	34
87	LHRH Agonists for the Treatment of Prostate Cancer: 2012. <i>Reviews in Urology</i> , 2012 , 14, 1-12	1	33
86	NX-1207: a novel investigational drug for the treatment of benign prostatic hyperplasia. <i>Expert Opinion on Investigational Drugs</i> , 2010 , 19, 305-10	5.9	29
85	KEYNOTE-676: Phase III study of BCG and pembrolizumab for persistent/recurrent high-risk NMIBC. <i>Future Oncology</i> , 2020 , 16, 507-516	3.6	25
84	Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer. <i>European Urology</i> , 2016 , 70, 438-44	10.2	25
83	The potential for NX-1207 in benign prostatic hyperplasia: an update for clinicians. <i>Therapeutic Advances in Chronic Disease</i> , 2011 , 2, 377-83	4.9	23
82	eRADicAte: A Prospective Evaluation Combining Radium-223 Dichloride and Abiraterone Acetate Plus Prednisone in Patients With Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2018 , 16, 149-154	3.3	22
81	Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Chemotherapy-naïve and CYP17 Inhibitor-naïve Patients: Follow-up from the ARADES and ARAFORS Trials. <i>European Urology Focus</i> , 2018 , 4, 547-553	5.1	21
80	Advances in the understanding of cancer immunotherapy. <i>BJU International</i> , 2015 , 116, 321-9	5.6	20
79	Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. <i>European Urology</i> , 2017 , 72, 10-13	10.2	19
78	Long-term efficacy and tolerability of once-yearly histrelin acetate subcutaneous implant in patients with advanced prostate cancer. <i>BJU International</i> , 2012 , 109, 226-32	5.6	19

77	The Role of Therapeutic Layering in Optimizing Treatment for Patients With Castration-resistant Prostate Cancer (Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence II). <i>Urology</i> , 2017 , 104, 150-159	1.6	18
76	Optimizing the role of androgen deprivation therapy in advanced prostate cancer: Challenges beyond the guidelines. <i>Prostate</i> , 2020 , 80, 527-544	4.2	18
75	Building on sipuleucel-T for immunologic treatment of castration-resistant prostate cancer. <i>Cancer Control</i> , 2013 , 20, 7-16	2.2	17
74	Results of a Real-world Study of Enzalutamide and Abiraterone Acetate With Prednisone Tolerability (REAACT). <i>Clinical Genitourinary Cancer</i> , 2019 , 17, 457-463.e6	3.3	16
73	Durability of the Prostatic Urethral Lift: 2-Year Results of the L.I.F.T. Study. <i>Urology Practice</i> , 2015 , 2, 26-32	0.8	13
72	Impact of darolutamide (DARO) on pain and quality of life (QoL) in patients (Pts) with nonmetastatic castrate-resistant prostate cancer (nmCRPC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 5000 ² 5000 ¹³		
71	Phase I Study of Seviteronel, a Selective CYP17 Lyase and Androgen Receptor Inhibitor, in Men with Castration-Resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2018 , 24, 5225-5232	12.9	12
70	Predicting Response and Recognizing Resistance: Improving Outcomes in Patients With Castration-resistant Prostate Cancer. <i>Urology</i> , 2017 , 109, 6-18	1.6	12
69	Polymer-delivered subcutaneous leuprolide acetate formulations achieve and maintain castrate concentrations of testosterone in four open-label studies in patients with advanced prostate cancer. <i>BJU International</i> , 2017 , 119, 239-244	5.6	12
68	Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2020 , 23, 680-688	6.2	9
67	A Review of the Prostatic Urethral Lift for Lower Urinary Tract Symptoms: Symptom Relief, Flow Improvement, and Preservation of Sexual Function in Men With Benign Prostatic Hyperplasia. <i>Current Bladder Dysfunction Reports</i> , 2015 , 10, 186-192	0.4	8
66	Fexapotide triflutate: results of long-term safety and efficacy trials of a novel injectable therapy for symptomatic prostate enlargement. <i>World Journal of Urology</i> , 2018 , 36, 801-809	4	8
65	Comparison of germline mutations in African American and Caucasian men with metastatic prostate cancer. <i>Prostate</i> , 2021 , 81, 433-439	4.2	8
64	An Approach Using PSA Levels of 1.5 ng/mL as the Cutoff for Prostate Cancer Screening in Primary Care. <i>Urology</i> , 2016 , 96, 116-120	1.6	8
63	Perioperative pembrolizumab therapy in muscle-invasive bladder cancer: Phase III KEYNOTE-866 and KEYNOTE-905/EV-303. <i>Future Oncology</i> , 2021 , 17, 3137-3150	3.6	8
62	Effect of abiraterone acetate and low-dose prednisone on PSA in patients with nonmetastatic castration-resistant prostate cancer: The results from IMAAGEN core study.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 5086-5086	2.2	7
61	Long-term follow-up from STAMP, a phase II trial, evaluating sipuleucel-T and concurrent (CON) vs sequential (SEQ) abiraterone acetate + prednisone in metastatic castration-resistant prostate cancer patients (pts).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 190-190	2.2	7
60	Clinical and safety outcomes of TALAPRO-2: A two-part phase III study of talazoparib (TALA) in combination with enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2019 , 37, 5076-5076	2.2	7

59	Optimizing the management of castration-resistant prostate cancer patients: A practical guide for clinicians. <i>Prostate</i> , 2020 , 80, 1159-1176	4.2	7
58	Androgen receptor inhibitor treatments: Cardiovascular adverse events and comorbidity considerations in patients with non-metastatic prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021 , 39, 52-62	2.8	7
57	Optimal timing of sipuleucel-T treatment in metastatic castration-resistant prostate cancer. <i>Canadian Journal of Urology</i> , 2015 , 22, 8048-55	0.8	7
56	A phase II trial of prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-refractory metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 83-83	2.2	6
55	Open Label Phase II Study of Enzalutamide With Concurrent Administration of Radium 223 Dichloride in Patients With Castration-Resistant Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2020 , 18, 416-422	3.3	6
54	Efficacy and safety of darolutamide in Japanese patients with nonmetastatic castration-resistant prostate cancer: a sub-group analysis of the phase III ARAMIS trial. <i>International Journal of Clinical Oncology</i> , 2021 , 26, 578-590	4.2	6
53	PROSPER: A phase 3 study of enzalutamide in nonmetastatic (M0) castration-resistant prostate cancer (CRPC) patients.. <i>Journal of Clinical Oncology</i> , 2014 , 32, TPS5094-TPS5094	2.2	5
52	The oral CYP17-Lyase (L) inhibitor VT-464 in patients with CRPC.. <i>Journal of Clinical Oncology</i> , 2015 , 33, 187-187	2.2	5
51	Alternative payment models. <i>Reviews in Urology</i> , 2017 , 19, 198-199	1	5
50	A Retrospective Claims Analysis of Advanced Prostate Cancer Costs and Resource Use. <i>Pharmacoeconomics - Open</i> , 2020 , 4, 439-447	2.1	5
49	Treatment of nonmetastatic castration-resistant prostate cancer: focus on second-generation androgen receptor inhibitors. <i>Prostate Cancer and Prostatic Diseases</i> , 2021 , 24, 323-334	6.2	5
48	Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503). <i>European Urology Oncology</i> , 2021 , 4, 543-552	6.7	5
47	Real-world genetic testing patterns in metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , 2021 , 17, 2907-2921	3.6	5
46	Indirect Comparison of Darolutamide versus Apalutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer. <i>Journal of Urology</i> , 2021 , 206, 298-307	2.5	5
45	Improved Survival With Enzalutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer.. <i>Journal of Clinical Oncology</i> , 2022 , JCO2200193	2.2	5
44	Three-year Active Surveillance Outcomes in a Contemporary Community Urology Cohort in the United States. <i>Urology</i> , 2019 , 130, 72-78	1.6	4
43	A New Sustained-release, 3-Month Leuprolide Acetate Formulation Achieves and Maintains Castrate Concentrations of Testosterone in Patients With Prostate Cancer. <i>Clinical Therapeutics</i> , 2019 , 41, 412-425	3.5	4
42	Optimizing the treatment of metastatic castration-resistant prostate cancer: a Latin America perspective. <i>Medical Oncology</i> , 2018 , 35, 56	3.7	4

41	A phase 2 trial of prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-refractory metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 5023-5023	2.2	4
40	Open-label phase II study evaluating the efficacy of concurrent administration of radium Ra 223 dichloride and abiraterone acetate in men with castration-resistant prostate cancer patients with symptomatic bone metastases.. <i>Journal of Clinical Oncology</i> , 2016 , 34, e16546-e16546	2.2	4
39	Current and Future Management of Locally Advanced and Metastatic Prostate Cancer. <i>Reviews in Urology</i> , 2020 , 22, 110-123	1	4
38	Efficacy and safety of fexapotide trifluate in outpatient medical treatment of male lower urinary tract symptoms associated with benign prostatic hyperplasia. <i>Therapeutic Advances in Urology</i> , 2019 , 11, 1756287218820807	3.2	3
37	Development and evaluation of the MiCheck test for aggressive prostate cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020 , 38, 683.e11-683.e18	2.8	3
36	ODM-201 and the CNS: A clinical perspective.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 275-275	2.2	3
35	Resetting the Bar of Castration Resistance - Understanding Androgen Dynamics in Therapy Resistance and Treatment Choice in Prostate Cancer. <i>Clinical Genitourinary Cancer</i> , 2021 , 19, 199-207	3.3	3
34	Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: An analysis of the phase III ARAMIS trial. <i>European Journal of Cancer</i> , 2021 , 154, 138-146	7.5	3
33	A comparison of prostate health index, total PSA, %free PSA, and proPSA in a contemporary US population-The MiCheck-01 prospective trial. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2020 , 38, 683.e1-683.e10	2.8	2
32	ARN-509 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without prior abiraterone acetate (AA) treatment.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 5026-5026	2.2	2
31	Safety results of the enzalutamide expanded access program in the United States and Canada for patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 5051-5051	2.2	2
30	Effect of denosumab versus zoledronic acid (ZA) in preventing skeletal-related events (SREs) in patients with metastatic bone disease: Subgroup analyses by baseline characteristics.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 9501-9501	2.2	2
29	Response to androgen signaling (AS)-directed therapy after treatment with abiraterone acetate (AA) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Post hoc analysis of study COU-AA-302.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 21-21	2.2	2
28	Review of the real-world prevalence of mHSPC, nmCRPC, mCRPC, and gene alterations associated with HRR in prostate cancer (PC).. <i>Journal of Clinical Oncology</i> , 2020 , 38, 229-229	2.2	2
27	Reply to Brandon A. Mahal, Anthony V. D'Amico, and Paul L. Nguyen Letter to the Editor re: Neal D. Shore, Fred Saad, Michael S. Cookson, et al. Oral Relugolix for Androgen Deprivation Therapy in Advanced Prostate Cancer. <i>N Engl J Med</i> 2020;382:2187-96. <i>European Urology</i> , 2020 , 78, e196-e197	10.2	2
26	Prostate-specific Antigen Progression in Enzalutamide-treated Men with Nonmetastatic Castration-resistant Prostate Cancer: Any Rise in Prostate-specific Antigen May Require Closer Monitoring. <i>European Urology</i> , 2020 , 78, 847-853	10.2	2
25	Cost-Effectiveness and Budget Impact of Emerging Minimally Invasive Surgical Treatments for Benign Prostatic Hyperplasia. <i>Journal of Health Economics and Outcomes Research</i> , 2021 , 8, 42-50	1.6	2
24	A phase 3, open-label, multicenter study of a 6-month pre-mixed depot formulation of leuprolide mesylate in advanced prostate cancer patients. <i>World Journal of Urology</i> , 2020 , 38, 111-119	4	2

23	Treating the patient and not just the cancer: therapeutic burden in prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2021 , 24, 647-661	6.2	2
22	A urologic oncology roundtable discussion: the role of disease monitoring in treatment decision-making for patients with metastatic castration-resistant prostate cancer. <i>Hospital Practice (1995)</i> , 2013 , 41, 78-80	2.2	1
21	Free autogenous muscle transplantation in rabbits: a technique for correction of urinary incontinence. <i>Journal of Urology</i> , 1985 , 134, 1047-9	2.5	1
20	Galeterone in men with CRPC: Results in four distinct patient populations from the ARMOR2 study.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 5029-5029	2.2	1
19	Association of alkaline phosphatase (ALP) with clinical outcomes in chemotherapy-naive patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results from COU-AA-302.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 27-27	2.2	1
18	Risk of Cognitive Effects in Comorbid Patients With Prostate Cancer Treated With Androgen Receptor Inhibitors. <i>Clinical Genitourinary Cancer</i> , 2021 , 19, 467.e1-467.e11	3.3	1
17	Real-world outcomes of second novel hormonal therapy or radium-223 following first novel hormonal therapy for mCRPC. <i>Future Oncology</i> , 2022 , 18, 35-45	3.6	0
16	Epidemiology and O-Serotypes of Extraintestinal Pathogenic Disease in Patients Undergoing Transrectal Ultrasound Prostate Biopsy: A Prospective Multicenter Study. <i>Journal of Urology</i> , 2021 , 205, 826-832	2.5	0
15	Patients' Preferences for delaying metastatic castration-resistant prostate cancer: Combining health state and treatment valuation. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021 , 39, 367.e7-367.e17	2.8	0
14	Primary Chemoablation of Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer Using UGN-102, a Mitomycin-Containing Reverse Thermal Gel (Optima II): A Phase 2b, Open-Label, Single-Arm Trial. <i>Journal of Urology</i> , 2022 , 207, 61-69	2.5	0
13	Review of second-generation androgen receptor inhibitor therapies and their role in prostate cancer management.. <i>Current Opinion in Urology</i> , 2022 , 32, 283-291	2.8	0
12	Reply to Potential underestimation of cerebrovascular events in the PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data. <i>Cancer</i> , 2020 , 126, 2935-2937	6.4	
11	Prospective evaluation of fexapotide trifluate injection treatment of Grade Group 1 prostate cancer: 4-year results. <i>World Journal of Urology</i> , 2020 , 38, 3101-3111	4	
10	An Outcomes Review of Minimally Invasive Transurethral Convective Water Vapor Energy (WAVE) Therapy for Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. <i>Current Bladder Dysfunction Reports</i> , 2016 , 11, 153-159	0.4	
9	Proper Sequencing of Treatment for Castrate Resistant Prostate Cancer. <i>Urology Practice</i> , 2014 , 1, 2-6	0.8	
8	Reduced Dose Intravesical Bacillus Calmette-Guérin: Why It Might Not Matter. <i>Bladder Cancer</i> , 2022 , 1-5	1	
7	A randomized phase 2 study evaluating optimal sequencing of sipuleucel-T (sip-T) and androgen deprivation therapy (ADT) in biochemically recurrent prostate cancer (BRPC): Preliminary clinical data.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 5041-5041	2.2	
6	Using a combination of plasma and urine biomarkers along with serum PSA in predicting prostate cancer and screening for high-risk cancer.. <i>Journal of Clinical Oncology</i> , 2014 , 32, e16026-e16026	2.2	

- 5 Time to chemotherapy following treatment with sipuleucel-T: Data from PROCEED.. *Journal of Clinical Oncology*, **2014**, 32, 5040-5040 2.2
- 4 Using a combination of urine and plasma biomarkers for the development of a scoring sytem that can diagnose and predict prognosis of prostate cancer.. *Journal of Clinical Oncology*, **2014**, 32, 163-163 2.2
- 3 Reply by Authors. *Journal of Urology*, **2021**, 205, 832 2.5
- 2 New treatments for patients with non-metastatic castration-resistant prostate cancer: A nursing perspective. *International Journal of Urological Nursing*, **2021**, 15, 47 0.8
- 1 Highlights in advanced prostate cancer from the 2012 American Urological Association Annual Meeting and the 2012 American Society of Clinical Oncology Annual Meeting. *Clinical Advances in Hematology and Oncology*, **2012**, 10, 1-24 0.6